These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2243511)

  • 1. 5-HT3 receptors.
    Kilpatrick GJ; Bunce KT; Tyers MB
    Med Res Rev; 1990; 10(4):441-75. PubMed ID: 2243511
    [No Abstract]   [Full Text] [Related]  

  • 2. [5-HT3-receptor-antagonists in therapy of rheumatic diseases].
    Müller W; Stratz T
    Z Rheumatol; 2003 Feb; 62(1):39-41. PubMed ID: 12624802
    [No Abstract]   [Full Text] [Related]  

  • 3. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists.
    Tyers MB
    Therapie; 1991; 46(6):431-5. PubMed ID: 1840227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics of serotonin 5-HT3 antagonists.
    Bonneterre J; Bercez C
    Pharmacoeconomics; 1996 Oct; 10(4):433-5. PubMed ID: 10163583
    [No Abstract]   [Full Text] [Related]  

  • 5. 5-HT3 receptors and central effects of ethanol.
    Kostowski W
    Pol J Pharmacol; 1996; 48(3):243-54. PubMed ID: 9112659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacology and clinical experiences with serotonin (5-HT3) receptor antagonists].
    Scholz J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):626-8. PubMed ID: 9445561
    [No Abstract]   [Full Text] [Related]  

  • 7. [Physiopathological and therapeutic perspectives on the new serotonin receptors: the type 4 receptor].
    Lefebvre H
    Rev Med Interne; 2000 Aug; 21(8):661-3. PubMed ID: 10989490
    [No Abstract]   [Full Text] [Related]  

  • 8. Serotonin receptor subtypes: implications for psychopharmacology.
    Cowen PJ
    Br J Psychiatry Suppl; 1991 Sep; (12):7-14. PubMed ID: 1840764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of 5-HT6 receptor antagonists.
    Reavill C; Rogers DC
    Curr Opin Investig Drugs; 2001 Jan; 2(1):104-9. PubMed ID: 11527001
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of generalized tendomyopathy (fibromyalgia) caused by blocking 5-HT3 receptors].
    Stratz T; Schochat T; Hrycaj P; Lacki J; Mennet P; Färber L; Schweiger C; Müller W
    Z Rheumatol; 1994; 53(6):335-8. PubMed ID: 7871905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pilot study with 5-HT3 antagonists. Good outcome in fibromyalgia pain].
    Stratz T; Müller W
    MMW Fortschr Med; 2002 Mar; 144(11):49. PubMed ID: 12066514
    [No Abstract]   [Full Text] [Related]  

  • 12. The clinical utility of pharmacological agents that act at serotonin receptors.
    Peroutka SJ; Sleight AJ; McCarthy BG; Pierce PA; Schmidt AW; Hekmatpanah CR
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):253-62. PubMed ID: 2562495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy.
    Karim F; Roerig SC; Saphier D
    Biochem Pharmacol; 1996 Sep; 52(5):685-92. PubMed ID: 8765466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT3 receptors.
    Tyers MB
    Ann N Y Acad Sci; 1990; 600():194-202; discussion 202-5. PubMed ID: 2252310
    [No Abstract]   [Full Text] [Related]  

  • 15. Centrally active 5-HT receptor agonists and antagonists.
    Middlemiss DN; Tricklebank MD
    Neurosci Biobehav Rev; 1992; 16(1):75-82. PubMed ID: 1553108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting.
    Loewen PS; Marra CA; Zed PJ
    Can J Anaesth; 2000 Oct; 47(10):1008-18. PubMed ID: 11032279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT3 receptor antagonists: a new class of antiemetics.
    Lancet; 1987 Jun; 1(8548):1470-1. PubMed ID: 2885458
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in the design of 5-HT6 receptor ligands with therapeutic potential.
    Witty D; Ahmed M; Chuang TT
    Prog Med Chem; 2009; 48():163-224. PubMed ID: 21544960
    [No Abstract]   [Full Text] [Related]  

  • 20. 5-HT3 receptors: pharmacologic and therapeutic aspects.
    Gyermek L
    J Clin Pharmacol; 1995 Sep; 35(9):845-55. PubMed ID: 8786244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.